Michael Moore began his career at the Paterson Institute for Cancer Research and Manchester University, where he was Reader in Experimental Oncology and Immunology and sometime Editor-in Chief of the British Journal of Cancer.
He entered the UK biotechnology industry in 1989, subsequently becoming a director of Xenova Group, which went public on NASDAQ (1994) and LSE (1996). He facilitated the divestment of the Group’s drug discovery division, assisted in the consolidation of Xenova as an oncology-focused business and played a major role in the acquisition and integration of the biologics company Cantab Pharmaceuticals (2000) in the capacity of Chief Scientific Officer.
In 2002, Dr Moore became Chief Executive Officer of Piramed Limited, a private UK-based biotechnology company dedicated to the discovery and development of small molecule inhibitors of PI 3-kinases. Piramed is credited with bringing this new class of drug to clinical trial on behalf of Cancer Research UK, the Institute of Cancer Research and the Ludwig Institute for Cancer Research. Piramed entered into collaboration with Genentech in 2005 with a headline valuation of $230 million and was subsequently acquired by Roche in 2008.
Dr Moore practises as a biopharmaceutical consultant and business angel with a portfolio of non-executive directorships, including Chairman of Trillium Therapeutics Inc., a private Toronto-based biologics company, Myotec, a speciality pharma company spun out of Imperial College London and Charité University, Berlin and Oxford BioTherapeutics, a cancer antibody therapy-based company. He is also a Professor Associate in the Department of Cancer Genetics and Pharmacogenomics in the Brunel Institute.